On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Makes Strides with Patented DehydraTECH™ Drug Delivery Platform

  • Lexaria Bioscience Corp. continues to make progress in the patenting and development of its DehydraTECH™ platform
  • Lexaria developed the patented DehydraTECH™ drug delivery platform as a safer alternative to inhalation of nicotine or cannabinoids
  • DehydraTECH™ has been shown to facilitate rapid uptake and highly targeted delivery of pharmaceuticals to the brain

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has levered innovation, research and development into operations in four market verticals: cannabis, hemp, nicotine, and pharmaceuticals. Lexaria already introduced the DehydraTECH™ drug delivery platform into commercial use and has a second-generation delivery platform ready for launch in 2020. Lexaria is the only company in the world to receive a patent for this improved oral delivery of all non-psychoactive cannabinoids including CBD. In fact, the company has 16 patents already granted along with more than 60 patents that are pending worldwide (http://ibn.fm/j08G0).

Lexaria has cannabinoid licensing agreements with various companies in North America. The popularity of cannabinoid products such as CBD is likely to increase in the future and the U.S. cannabis market alone is projected to grow substantially in the future (http://ibn.fm/LsBtn). Lexaria’s delivery technology is already being used by the CBD/hemp industry and could experience radical growth in step with the industry.

The DehydraTECH™ drug delivery platform is an innovative technology that was developed as a way to safely and effectively deliver substances both to the bloodstream and to the brain via the oral ingestion route. Substances such as nicotine and cannabidiol are historically inhaled, a choice that is harmful to health compared with non-inhalation methods.

Inhalation can be problematic and dangerous especially for individuals who may have other medical issues. The DehydraTECH™ drug delivery platform can be used to deliver substances in edible or in beverage form, and in capsules, pills, syrups and more. Brands in both Canada and the USA have licensed DehydraTECH™ to make their CBD and cannabis beverages best-in-class.

Not only is ingestion a much safer form of drug delivery, but DehydraTECH™ also delivers the active ingredient of the substance at a rate that is up to five to ten times faster compared with traditional edible products. A 2018 European clinical study demonstrated that 317 percent more CBD was delivered within half an hour when compared with a positive control of equal strength (http://ibn.fm/pXIxY). The substance being delivered is also rapidly absorbed which means that people can achieve the effect they are looking for more quickly than was previously the case with edibles. For people looking for quick relief of pain, DehydraTECH is a blessing.

Many human receptor cells are clustered primarily in the brain or central nervous system, so in order to treat conditions, drugs need to effectively reach these areas of the body which has historically been difficult to do. Research studies done with animals have demonstrated delivery of 1,937 percent more cannabidiol (and over 500 percent more nicotine) into the brain tissue after 8 hours when using the enhanced DehydraTECH™ when compared with using generic industry MCT coconut-oil formulations. Greater effectiveness can mean safer, lower doses. The increased bioavailability and speed of onset are important factors when delivering substances to the brain and is especially important for people who need rapid relief from unpleasant and debilitating symptoms.

Studies done in the laboratory have also shown dramatically improved oral nicotine delivery using the DehydraTECH™ platform. Lexaria has partnered with one of the world’s largest tobacco companies to help fund the research and development of DehydraTECH™ as it relates to nicotine delivery (http://ibn.fm/rlVJn).

A big advantage of the DehydraTECH™ drug delivery platform when it comes to nicotine is that the delivery is fast when compared with other oral forms of nicotine – such as nicotine lozenges or nicotine gum. Users are less likely to get frustrated if they can feel the effects of the nicotine faster when taken in through the oral route. Lower-risk technologies are needed when it comes to nicotine, which is something that the government has recognized since smoking is known to be deadly. Therefore, technology developed to reduce health risks is highly beneficial.

DehydraTECH™ drug delivery platform has applications for the pharmaceutical industry and could be used to deliver fat-soluble drugs. It also could be used to deliver NSAID medications such as ibuprofen or acetylsalicylic acid. DehydraTECH™ has the advantage of allowing substances to bypass first phase liver metabolism.

The technology uses GRAS (Generally Recognized As Safe) food ingredients and further advantages are that the technology removes the bitter flavors and odors of many drugs. This is beneficial because artificial sweeteners do not need to be added to the product to enhance its taste and make it palatable. Sugar may be an issue, especially for people who have diabetes, thus a sugar-free product would be a healthier option.

Lexaria was recently granted two granted patents related to the treatment of heart disease, Alzheimer’s, Parkinson’s and schizophrenia. The treatment of these and other types of neurological disorders in particular has been problematic due to the blood-brain barrier – which makes it difficult for the brain to take up the needed medications. This barrier is formed by endothelial cells which function to prevent dangerous substances from passing into the brain from blood vessels, but the problem is that this also often stops helpful drugs from being able to enter the brain. The patented DehydraTECH™ drug delivery platform helps overcome this limitation to rapidly deliver essential medications to the brain.

For more information, visit the company’s website at www.LexariaBioscience.com

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at  http://ibn.fm/LXRP

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

Archives

Select A Month
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • July 2015
  • June 2015
  • May 2015
  • April 2015
  • March 2015
  • February 2015
  • January 2015
  • December 2014
  • November 2014
  • October 2014
  • September 2014
  • August 2014
  • July 2014
  • June 2014
  • May 2014
  • April 2014
  • March 2014
  • February 2014
  • January 2014
  • December 2013
  • November 2013
  • October 2013
  • September 2013
  • August 2013
  • July 2013
  • June 2013
  • May 2013
  • April 2013
  • March 2013
  • February 2013
  • January 2013
  • December 2012
  • November 2012
  • October 2012
  • September 2012
  • August 2012
  • July 2012
  • June 2012
  • May 2012
  • April 2012
  • March 2012
  • February 2012
  • January 2012
  • December 2011
  • November 2011
  • October 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • April 2011
  • March 2011
  • February 2011
  • January 2011
  • December 2010
  • November 2010
  • October 2010
  • September 2010
  • August 2010
  • July 2010
  • June 2010
  • May 2010
  • April 2010
  • March 2010
  • February 2010
  • January 2010
  • December 2009
  • November 2009
  • October 2009
  • September 2009
  • August 2009
  • July 2009
  • June 2009
  • May 2009
  • April 2009
  • March 2009
  • February 2009
  • January 2009
  • December 2008
  • November 2008
  • October 2008
  • September 2008
  • August 2008
  • July 2008
  • June 2008
  • May 2008
  • April 2008
  • March 2008
  • February 2008
  • January 2008
  • December 2007
  • November 2007
  • October 2007
  • September 2007
  • August 2007
  • July 2007
  • June 2007
  • May 2007
  • April 2007
  • March 2007
  • February 2007
  • January 2007
  • December 2006
  • November 2006
  • October 2006
  • September 2006
  • August 2006
  • July 2006
  • June 2006
  • May 2006
  • April 2006
  • March 2006
  • January 2006
  • December 2005
  • October 2005
  • September 2005
  • Market Basics

    New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

    The Basics

    Newsletter Publishers

    Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

    Register

    Public Companies

    Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

    Get Covered